You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

933 Results
Document
Jul 2021
Document
Jul 2021
Document
Jul 2021
Document
Sep 2021
Document
Sep 2021
Guidelines and Advice
Status: Current
Version: 3.1
Oct 2024
Document
Sep 2021
Document
Sep 2021
Document
Sep 2021
Document
Oct 2021
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Funding:
Exceptional Access Program
    olaparib - For the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated, human epidermal growth factor receptor 2-negative high risk early breast cancer, based on criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
olaparib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2024
Document
Nov 2021

Pages